Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus METANDREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus METANDREN.
HALOTESTIN vs METANDREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Category C
Category C
Androgen
Androgen